Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Mark Bernard Leick, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston2021Medical Oncology
Johns Hopkins Hospital, Baltimore2017Internal Medicine
Georgetown, Washington DCMD2014Medicine
University of Arizona, TucsonBS2009Bioengineering, Biochemistry, Molecular Biology

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K12CA087723 (GRAUBERT, TIMOTHY A) Jul 1, 2000 - Mar 31, 2023
    NIH
    Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology
    Role: Co-Investigator
  2. PST-37-22
    Mark Foundation for Cancer Research Physician-Scientist of the Damon Runyon Cancer Research Foundation

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022 Sep 12. PMID: 36097221.
    Citations:    
  2. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Maus MV. Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals. Clin Infect Dis. 2022 Aug 24; 75(1):e869-e873. PMID: 35278306; PMCID: PMC9402689.
    Citations:    Fields:    
  3. Leick M, Chen YB. Paraneoplastic Pulmonary Alveolar Proteinosis. Am J Respir Crit Care Med. 2022 06 15; 205(12):e55. PMID: 35353650.
    Citations:    Fields:    Translation:Humans
  4. Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, Maus MV. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022 05 09; 40(5):494-508.e5. PMID: 35452603; PMCID: PMC9107929.
    Citations: 1     Fields:    Translation:HumansCells
  5. Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022 04 14; 139(15):2306-2315. PMID: 35167655; PMCID: PMC9012129.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  6. Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. CAR T cell killing requires the IFN?R pathway in solid but not liquid tumours. Nature. 2022 04; 604(7906):563-570. PMID: 35418687.
    Citations: 2     Fields:    Translation:HumansCells
  7. Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KME, Frigault MJ, Maus MV. Blockade or Deletion of IFN? Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discov. 2022 03 01; 3(2):136-153. PMID: 35015685.
    Citations: 5     Fields:    Translation:HumansCells
  8. How J, Gallagher KME, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia. 2022 04; 36(4):1176-1179. PMID: 35217807; PMCID: PMC8873343.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  9. Leick M, Chen YB. A glimpse into what happens after PTCy. Blood. 2022 01 27; 139(4):479-481. PMID: 35084475.
    Citations:    Fields:    Translation:Humans
  10. Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022 01; 10(1). PMID: 34996813; PMCID: PMC8744112.
    Citations: 4     Fields:    Translation:Humans
  11. Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986. PMID: 34342642; PMCID: PMC8361461.
    Citations: 4     Fields:    Translation:Humans
  12. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Brini G, Grauwet K, Maus MV. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv. 2021 May 03. PMID: 33972942; PMCID: PMC8109204.
    Citations: 1     
  13. Leick MB, Maus MV, Frigault MJ. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Mol Ther. 2021 02 03; 29(2):433-441. PMID: 33130313; PMCID: PMC7854294.
    Citations: 9     Fields:    Translation:HumansCells
  14. Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer. 2020 09; 8(2). PMID: 32900862.
    Citations: 5     Fields:    Translation:HumansCells
  15. Leick MB. Telephone. N Engl J Med. 2020 Dec 10; 383(24):2304-2305. PMID: 32813943.
    Citations: 1     Fields:    Translation:Humans
  16. Leick M, Gittelman RM, Yusko E, Sanders C, Robins H, DeFilipp Z, Nikiforow S, Ritz J, Chen YB. T Cell Clonal Dynamics Determined by High-Resolution TCR-ß Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 09; 26(9):1567-1574. PMID: 32417490.
    Citations: 4     Fields:    Translation:HumansCells
  17. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019 11 14; 7(1):304. PMID: 31727131.
    Citations: 75     Fields:    Translation:HumansAnimalsCells
  18. Maus MV, Leick MB, Cornejo KM, Nardi V. Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. N Engl J Med. 2019 Nov 14; 381(20):1951-1960. PMID: 31722157.
    Citations: 1     Fields:    Translation:Humans
  19. Leick M, Hunter B, DeFilipp Z, Dey BR, El-Jawahri A, Frigault M, McAfee S, Spitzer TR, O'Donnell P, Chen YB. Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplant. 2020 04; 55(4):758-762. PMID: 31649343.
    Citations: 1     Fields:    Translation:Humans
  20. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058. PMID: 31332324.
    Citations: 141     Fields:    Translation:HumansAnimalsCells
  21. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 09 12; 134(11):860-866. PMID: 31320380; PMCID: PMC7022436.
    Citations: 57     Fields:    Translation:HumansCells
  22. Leick M, Maus MV. Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discov. 2019 Apr; 9(4):466-468. PMID: 30936218.
    Citations: 4     Fields:    Translation:Humans
  23. Leick MB, Maus MV. CAR-T cells beyond CD19, UnCAR-Ted territory. Am J Hematol. 2019 05; 94(S1):S34-S41. PMID: 30632631.
    Citations: 1     Fields:    Translation:Humans
  24. Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018 06; 31(2):158-165. PMID: 29909916.
    Citations: 3     Fields:    Translation:Humans
  25. Leick MB, Levis MJ. The Future of Targeting FLT3 Activation in AML. Curr Hematol Malig Rep. 2017 06; 12(3):153-167. PMID: 28421420.
    Citations: 21     Fields:    Translation:HumansCells
  26. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  27. Leick MB, Shoff CJ, Wang EC, Congress JL, Gallicano GI. Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am J Stem Cells. 2012; 1(1):59-74. PMID: 23671798.
    Citations: 23     
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Leick's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (93)
Explore
_
Co-Authors (53)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.